Why Is Entresto (Sacubitril/Valsartan) So Hard to Find? [Explained for 2026]

If you've ever stood at a pharmacy counter and been told your Entresto isn't in stock, you're not alone. Sacubitril/valsartan — sold under the brand name Entresto — is one of the most important heart failure medications available, yet patients and caregivers across the country report difficulty filling it consistently. This guide explains exactly why that happens and what you can do about it.

What Is Entresto and Who Needs It?

Entresto (sacubitril/valsartan) is a first-in-class angiotensin receptor-neprilysin inhibitor (ARNI) approved by the FDA in July 2015. It combines two active ingredients — sacubitril, which raises beneficial natriuretic peptides, and valsartan, an angiotensin receptor blocker — into a single twice-daily tablet.

It is prescribed to reduce the risk of cardiovascular death and hospitalization in adults with chronic heart failure with reduced ejection fraction (HFrEF), and for children aged 1 and older with symptomatic heart failure. Approximately 6 million Americans live with heart failure, and Entresto is now a cornerstone of guideline-directed medical therapy. With demand this high, supply pressures are inevitable.

Is There an Actual Entresto Shortage in 2026?

As of 2026, there is no formal FDA-listed shortage of Entresto or generic sacubitril/valsartan. However, "no shortage" doesn't mean "easy to find." Several structural factors create real-world gaps between what's prescribed and what's on pharmacy shelves.

Why Entresto Can Still Be Hard to Find: The Real Reasons

Here are the key factors driving availability challenges in 2026:

1. The Brand-to-Generic Transition Is Still Underway

Entresto's core U.S. patent expired in July 2025, and the FDA approved generic sacubitril/valsartan in May 2024. Multiple manufacturers — including Novadoz Pharmaceuticals, Camber, Ascend, and Macleods Pharma — began producing it, but pharmacy shelves needed time to catch up. During this transition period, some pharmacies stock the brand but not the generic, others carry generics only, and not all generic makers have reached full production capacity.

2. Manufacturing Complexity Makes Shortfalls More Likely

Sacubitril/valsartan isn't a simple pill to manufacture. The drug requires co-crystallization of two active pharmaceutical ingredients (sacubitril and valsartan) in precise molecular ratios. This co-crystal formulation is technically demanding and more prone to production variability than conventional single-compound tablets. Even when demand is stable, manufacturing hiccups can ripple through the supply chain.

3. Demand Has Never Been Higher

Novartis reported $7.8 billion in Entresto global sales in 2024 — and demand hasn't slowed even as generics entered the market. Current heart failure guidelines from the American College of Cardiology (ACC) and American Heart Association (AHA) recommend Entresto as the preferred ARNI in the "quadruple therapy" regimen for HFrEF. As more cardiologists and primary care physicians follow these guidelines, more patients are being started on the drug each year.

4. Insurance and Step Therapy Add Delays

Even when the drug is physically in stock, insurance barriers can create delays that feel like a shortage. Many plans require prior authorization for Entresto, and step therapy policies mandate that patients try an ACE inhibitor or ARB first before approval is granted. These administrative hurdles can stall your prescription for days or even weeks, leaving you without the medication you need.

5. Pharmacy Stocking Practices Vary Widely

Not every pharmacy stocks every medication in every strength. Independent pharmacies often carry only one or two strengths of sacubitril/valsartan, and smaller chains may not stock the brand at all once generics became available. The pharmacy you used last year may no longer carry what you need. What one pharmacy is out of, another two miles away may have on the shelf.

What Should You Do If You Can't Find Entresto?

Here are practical steps to take when your pharmacy doesn't have sacubitril/valsartan in stock:

Ask about the generic. If you're on brand-name Entresto, ask whether generic sacubitril/valsartan is available. It's bioequivalent and significantly cheaper.

Call nearby pharmacies. Ring 3–5 pharmacies in your area and ask specifically about your strength (24/26 mg, 49/51 mg, or 97/103 mg).

Use medfinder. medfinder calls pharmacies near you to check which ones can fill your Entresto prescription — saving you hours of phone calls.

Contact your cardiologist or prescriber. They may be able to provide samples, contact specialty pharmacies, or assist with prior authorization appeals.

Do NOT stop Entresto abruptly. Stopping sacubitril/valsartan suddenly can worsen heart failure or cause rebound high blood pressure. Always talk to your doctor before discontinuing.

Is the Availability Getting Better?

Yes. The outlook for 2026 is more optimistic than 2025. With multiple generic manufacturers now producing sacubitril/valsartan and the brand patent fully expired, supply is expected to stabilize and broaden. Pharmacists in areas with established supply chains report that the generic is generally available for next-day ordering when not on the shelf.

How medfinder Can Help

medfinder is a service that contacts pharmacies near you by phone to find out which ones have sacubitril/valsartan in stock and can fill your prescription. You provide your medication, strength, and location — medfinder does the calling and texts you the results. Learn more about how to find Entresto near you.

Heart failure is serious, and so is consistent access to your medication. Don't give up after one pharmacy says no.